This site is intended for healthcare professionals

NICE recommends use of Emgality in migraine in adults with episodic and chronic migraine.- Eli Lilly

Read time: 1 mins
Last updated:20th Dec 2021
Published:19th Nov 2020
Eli Lilly and Company announced that the National Institute for Health and Care Excellence (NICE) has recommended Emgality (galcanezumab) as an option for the prevention of migraine in adults with episodic and chronic migraine. The decision is based on clinical trials comparing galcanezumab with placebo, in which galcanezumab halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more preventative medicines.The NICE decision was based upon clinical-effectiveness results from the CONQUER, REGAIN, EVOLVE-1 and EVOLVE-2 trials which showed that galcanezumab reduced the number of monthly migraine days more than placebo for episodic and chronic migraine. These studies have shown that the most common side effects with galcanezumab (which may affect more than 1 in 10 people) are reactions at the site of injection such as pain, redness, itching, bruising or swelling.
Condition: Migraine/Headache
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.